NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 16:25இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Aarti Pharmalabs Q2 FY27 Call: Standalone Revenue Up 47% to ₹613 Cr; Targets ₹1,000 Cr CDMO Revenue
Aarti Pharmalabs reported its highest-ever standalone quarterly revenue of ₹613 crore in Q2 FY27, up 47% YoY from ₹417 crore, with EBITDA expanding 84% YoY to ₹136 crore and margins reaching 22.2%. Profit after tax rose 2.75x YoY to ₹66 crore on strong execution and steroid API capacity ramp-up. Xanthine derivatives contributed 50% of turnover, APIs 30%, and CDMO/CMO 13%, with CDMO targeting 40-50% growth this year. Management reiterated a medium-term target of ₹800-1,000 crore revenue from CDMO over the next 2-3 years, driven by 39 commercialized projects.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 FY27 earnings conference call held on October 29, 2026.
ஏன் இது முக்கியம்Confirms strong operating leverage with EBITDA margins crossing 22% and provides concrete visibility on CDMO scaling towards a ₹1,000 crore pipeline over 2-3 years.
📅 குறுகிய காலம்Earnings commentary reflects positive momentum and raw material pass-through, though shipment constraints slightly weighed on Xanthine dispatches during Q2.
📈 நீண்ட காலம்Commissioning of Atali Phase 1 and dedicated Block 2 positions the company to transform from a Xanthine-dependent business into a diversified CDMO and API player.
⚠ அபாய எச்சரிக்கைகள்
Elevated raw material costs linked to geopolitical turmoil
Customer clinical trial dropouts impacting the under-development CDMO pipeline
👀 கவனிக்க வேண்டியவை
Track the full capitalization and commercialization of Atali Phase 1 in Q3 FY27 and the sequential ramp-up of expanded Xanthine capacity through Q4 FY27.
Aarti Pharmalabs H1 FY27 Revenue at ₹1,146 Cr, EBITDA Margin at 23.3%
Aarti Pharmalabs released its Q2/H1 FY27 investor presentation highlighting standalone/consolidated operational updates. Consolidated operational income reached ₹1,146.2 Cr for H1 FY27 with EBITDA of ₹267.3 Cr (23.3% margin) and PAT of ₹147.6 Cr (12.9% margin). The company completed its Tarapur Xanthine expansion to 9,600+ MTPA (up from 5,000 MTPA), aiming to boost global market share from 15-20% to 20-25%. CDMO sales are estimated at ₹276 Cr for FY27E, up from ₹208 Cr in FY26, with 23 active customers across 59 projects.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarti Pharmalabs issued its Q2 FY27 earnings presentation detailing H1 FY27 performance, operational scale, and segment-wise expansion plans.
ஏன் இது முக்கியம்Demonstrates margin resilience (23.3% EBITDA margin) despite raw material headwinds and highlights structural scale in Xanthine derivatives and higher-margin CDMO lines.
📅 குறுகிய காலம்Presentation gives detailed operating context to Q2 results; near-term stock reaction will correlate with detailed Q2 P&L performance versus consensus expectations.
📈 நீண்ட காலம்Doubling of Xanthine capacity to 9,600+ MTPA and growth in CDMO pipeline provide long-term operating leverage and potential global market share expansion.
⚠ அபாய எச்சரிக்கைகள்
Elevated raw material costs linked to geopolitical tensions
Ramp-up execution risk for expanded capacities at Tarapur and Atali sites
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up at the expanded Tarapur Xanthine facility through FY27 and commercial scaling of CDMO projects from development to commercial supply.
Aarti Pharmalabs Q2 Standalone Revenue Up 46.8% to ₹612.6 Cr; Appoints New CFO
Aarti Pharmalabs reported standalone revenue from operations of ₹612.59 Cr for Q2 FY27 (quarter ended Sep 30, 2026), marking a 46.8% increase compared to ₹417.29 Cr in Q2 FY26. The company approved the appointment of Smt. Vibha Thakkar as CFO effective October 31, 2026, succeeding Shri Piyush Lakhani who resigned. In exceptional items, the company recognized a provision of ₹2.04 Cr towards a disputed Gujarat Stamp Act demand of ₹59.5 Cr (stamp duty ₹25.0 Cr and penalty ₹34.5 Cr), challenging the balance of ₹57.46 Cr via a writ petition.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarti Pharmalabs announced Q2 FY27 unaudited results showing strong revenue growth alongside a CFO transition to Smt. Vibha Thakkar.
ஏன் இது முக்கியம்Demonstrates robust top-line momentum in bulk drugs/APIs while highlighting an ongoing legal contingency regarding stamp duty from its past demerger.
📅 குறுகிய காலம்The market is likely to react positively to the strong top-line recovery, though focus will remain on operating cash flow trends and the legal resolution of the stamp duty matter.
📈 நீண்ட காலம்Growth sustainability will hinge on successful ramp-up of the greenfield Atali CDMO facility and Tarapur brownfield expansion.
⚠ அபாய எச்சரிக்கைகள்
Pending litigation in the Gujarat High Court regarding a ₹57.46 Cr stamp duty and penalty demand
Working capital expansion, leading to reduced H1 cash flow from operations (₹29.99 Cr vs ₹96.52 Cr YoY)
👀 கவனிக்க வேண்டியவை
Track the outcome of the writ petition filed in the Gujarat High Court concerning the ₹57.46 Cr contingent stamp duty liability, along with execution timelines for the ongoing Atali and Tarapur capex.
Aarti Pharmalabs Appoints Vibha Thakkar as CFO Following Piyush Lakhani's Resignation
Aarti Pharmalabs has announced that CFO Piyush Lakhani has resigned to pursue outside opportunities and will step down on October 30, 2026. Smt. Vibha Thakkar has been appointed as the new Chief Financial Officer and Key Managerial Personnel effective October 31, 2026. Thakkar brings over 18 years of finance experience, most recently serving as AVP-Finance & Accounts at NOCIL Limited. Alongside leadership updates, the company reported standalone Q2 revenue from operations of Rs 61,258.69 lakhs compared to Rs 41,728.78 lakhs in Q2 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுPiyush Lakhani resigned as CFO effective October 30, 2026, and Smt. Vibha Thakkar takes over the role on October 31, 2026.
ஏன் இது முக்கியம்A transition in CFO impacts financial strategy and capital allocation, especially as the company manages major expansions and legal tax disputes.
Outgoing CFO Relieving Date: அக்டோபர் 30, 2026Incoming CFO Effective Date: அக்டோபர் 31, 2026Q2 Standalone Revenue from Operations: Rs 61,258.69 lakhsContingent Stamp Duty Liability: Rs 5,746.00 lakhs
📅 குறுகிய காலம்Leadership transition appears orderly with immediate backfill, likely minimizing disruption to daily financial operations.
📈 நீண்ட காலம்Limited operational disruption expected given the immediate appointment of an experienced industry professional.
⚠ அபாய எச்சரிக்கைகள்
Pending litigation for Rs 5,746.00 lakhs stamp duty and penalty before Gujarat High Court
Key managerial turnover at the CFO level
👀 கவனிக்க வேண்டியவை
Track the smooth transition in finance leadership and monitor proceedings in the Gujarat High Court concerning the Rs 5,746.00 lakh contingent stamp duty liability.
Aarti Pharmalabs has filed a Writ Petition before the Hon'ble High Court of Gujarat at Ahmedabad challenging an order dated August 29, 2026, issued by the Superintendent of Stamps, Gandhinagar. The challenged order had levied stamp duty and penalties totaling Rs 59.50 crore concerning its demerger scheme sanctioned by NCLT Ahmedabad in September 2022. The demanded sum represents approximately 27.9% of the company's TTM PAT (Rs 213 crore) and about 3.0% of its net worth (Rs 1,982 crore). The company is contesting the liability legally, making the final cash outflow uncertain pending judicial proceedings.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarti Pharmalabs moved to court by filing a Writ Petition in the Gujarat High Court to contest an adverse Rs 59.50 crore stamp duty and penalty order.
ஏன் இது முக்கியம்A confirmed liability of Rs 59.50 crore would equate to over a quarter of TTM profit (Rs 213 crore), which could impact cash flows if interim relief is denied or deposit is mandated.
Stamp duty & penalty demand: Rs. 59,50,00,000/-Demand vs TTM PAT: ~27.9%Demand vs Net worth: ~3.0%NCLT order date: செப்டம்பர் 21, 2022Stamp authority order date: ஆகஸ்ட் 29, 2026
📅 குறுகிய காலம்Watch for whether the Gujarat High Court admits the petition and grants a stay on recovery, or directs any pre-deposit of the disputed amount.
📈 நீண்ட காலம்Resolution of legacy demerger stamp duty liabilities will remove potential overhang on balance sheet reserves and cash balances.
⚠ அபாய எச்சரிக்கைகள்
Potential one-off cash outflow or pre-deposit requirement if stay is conditional
Adverse ruling could impact profitability via provisioning
👀 கவனிக்க வேண்டியவை
Track High Court proceedings for potential interim relief or stay orders, as well as any provisions or contingent liability disclosures in the upcoming Q2 FY27 financial results.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Aarti Pharmalabs AGM Approves ₹2/Share Dividend and Management Restructuring
Aarti Pharmalabs announced the voting results of its 7th Annual General Meeting held on September 22, 2026, where all resolutions passed with the requisite majority. Shareholders approved a final dividend of ₹2 per share on face value ₹5, as well as significant leadership changes effective October 1, 2026. Rashesh C. Gogri was appointed Managing Director (supported by 90.19% total votes), while Hetal Gogri Gala's designation transitioned from Managing Director to Whole-time Director (passed with 89.67% total votes). Notably, institutional investors showed split sentiment on management changes, with ~45-48% of institutional votes cast against both resolutions.
உச்சம் நம்பிக்கை
என்ன மாறியதுRashesh C. Gogri will take over as Managing Director from October 1, 2026, while former MD Hetal Gogri Gala shifts to Whole-time Director and Rajendra Gogri retires from the Board.
ஏன் இது முக்கியம்The realignment sets executive leadership ahead of major expansion milestones (Tarapur and Atali sites), though the notable institutional dissent (~45-48% against) reflects heightened scrutiny over promoter leadership changes.
Final Dividend per Share: ₹ 2/-Total Votes Polled % of Outstanding: 62.33%Institutional Vote Against MD Appointment: 45.26%Institutional Vote Against Designation Change: 47.70%
📅 குறுகிய காலம்Limited operational impact as the dividend and leadership changes were previously proposed and are now formalised.
📈 நீண்ட காலம்Executive oversight shifts to Rashesh C. Gogri as the business executes its CDMO push and capacity expansions.
⚠ அபாய எச்சரிக்கைகள்
High institutional dissent (~45-48%) on management redesignation and appointment resolutions.
👀 கவனிக்க வேண்டியவை
Track the formal leadership transition taking effect on October 1, 2026, and watch for any commentary on institutional feedback during upcoming quarterly earnings.
Aarti Pharmalabs AGM: Guides 15-18% CAGR, FY27 Capex at ~Rs 400 Cr with Atali & Tarapur Projects
Aarti Pharmalabs released its 7th AGM presentation outlining multi-year capex and medium-term guidance. The company guided for a 15-18% Revenue & EBITDA CAGR over the next 3-4 years, backed by capex of ~INR 400 crore in FY26 and similar capex planned for FY27 (~20.3% of TTM revenue). Major ongoing expansions include the INR 400 crore Greenfield Atali site (~450 KL Block 1, ~80% operationalized by Q4FY26) and a brownfield Tarapur project worth INR 210 crore (9,000 MTPA Xanthine capacity, operational in Q1FY27). Additionally, the company announced capex for Atali Block 2 targeting specific CDMO/CMO projects, with groundbreaking slated for Q3FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarti Pharmalabs provided detailed execution timelines for Atali and Tarapur expansions, initiated Atali Block 2 CDMO expansion, and formally guided for 15-18% Revenue and EBITDA CAGR.
ஏன் இது முக்கியம்The combined ongoing capex of over INR 610 cr represents >30% of TTM revenue, providing substantial volume visibility for CDMO/CMO and Xanthine derivatives over the next 2-4 years.
📅 குறுகிய காலம்Presents a clear growth roadmap and reassuring medium-term targets following a subdued FY26, supporting investor sentiment.
📈 நீண்ட காலம்Scaling CDMO capabilities at Atali (scalable 8-10x) and deepening Xanthine market share (currently 15-20% globally) structurally strengthens business mix and operating margins.
⚠ அபாய எச்சரிக்கைகள்
Project execution and qualification delays at Atali and Tarapur.
Susceptibility to raw material volatility and forex fluctuations (e.g., INR 33.2 cr forex loss in FY26).
👀 கவனிக்க வேண்டியவை
Monitor commercialization milestones at Atali Phase 1 in Q4FY26 and Tarapur Xanthine unit ramp-up in Q1FY27, alongside margin trajectory toward the guided 15-18% EBITDA growth.
The Office of the Superintendent of Stamps, Gujarat, has levied a total demand of ₹59.50 Cr on Aarti Pharmalabs regarding the adjudication of stamp duty on its 2022 demerger from Aarti Industries. The demand consists of ₹25.0 Cr base stamp duty, ₹25.0 Cr penalty, and an additional penalty of ₹9.50 Cr. The aggregate claim represents ~27.9% of the company's TTM net profit (₹213 Cr) and ~3.0% of its net worth (₹1,982 Cr). The company stated it has strong grounds on merits and will legally challenge the order.
உச்சம் நம்பிக்கை
என்ன மாறியதுGujarat stamp authorities issued an adverse demand order for ₹59.50 Cr (duty + penalties) on the 2022 demerger from Aarti Industries.
ஏன் இது முக்கியம்The liability is sizable relative to annual profitability (~28% of TTM PAT), posing cash outflow risk if legal relief or stay is not obtained.
Total demand: Rs. 59,50,00,000/-Base stamp duty: Rs. 25 CroresPenalties levied: Rs. 34.50 CroresDemand vs TTM PAT: ~27.9%Demand vs Net Worth: ~3.0%
📅 குறுகிய காலம்May weigh on stock sentiment in the near term as the market assesses potential cash provisioning or pre-deposit requirements.
📈 நீண்ட காலம்Limited structural risk to ongoing operations, though resolution in stamp duty litigation typically involves extended legal timelines.
⚠ அபாய எச்சரிக்கைகள்
Potential cash outflow of up to ₹59.50 Cr if legal challenge fails
Requirement of statutory pre-deposit to secure a stay on demand
👀 கவனிக்க வேண்டியவை
Track the filing of appeals, application for interim stay, and whether any mandatory pre-deposit is required during the appellate process.
Aarti Pharmalabs reported Q1 FY27 consolidated revenue of ₹535.8 Cr, showing strong operational performance with EBITDA margins expanding to 24.75% from 22.12% in FY26. The company has successfully commissioned its Xanthine capacity expansion at Tarapur Unit 5, reaching 9,600 MTPA, which is expected to increase its global market share to 20-25%. The CDMO segment continues to scale, with FY26 sales at ₹276 Cr and 37 commercial projects currently active. Additionally, a 6-week debottlenecking at the Unit 4 Steroid block has unlocked 33% additional capacity.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned to a higher capacity base in its Xanthine business and completed critical debottlenecking in its Steroid API block, while shifting to JV accounting for Ganesh Polychem.
ஏன் இது முக்கியம்The capacity expansion in Xanthines (Caffeine) targets a dominant 20-25% global market share, while the scaling CDMO business and Atali Greenfield site provide a long-term growth runway beyond generic APIs.
Q1 FY27 Consolidated Revenue: ₹535.8 கோடிQ1 EBITDA Margin: 24.75%Xanthine Capacity: 9,600 MTPAQ1 வருவாய் vs TTM வருவாய்: 29.4%Net Debt to Equity: 0.32x
📅 குறுகிய காலம்The stock may react positively to the margin expansion and the successful commissioning of the Xanthine capacity, which provides immediate volume growth potential.
📈 நீண்ட காலம்Structural growth is supported by the 'China+1' strategy in Xanthines and the 80-acre Atali land bank, which allows for 8-10x scaling of the initial CDMO capacity.
⚠ அபாய எச்சரிக்கைகள்
Elevated raw material prices due to geopolitical tensions
👀 கவனிக்க வேண்டியவை
Monitor the volume ramp-up of the newly commissioned 9,600 MTPA Xanthine capacity and the utilization levels of the Atali Greenfield Phase 1 (450+ kL) for CDMO growth. Watch for the impact of elevated raw material prices on margins in the coming quarters.
Rs 149 Cr Capex for 405 KL Capacity Addition & Strong Q1 PAT Growth of 49% YoY
Aarti Pharmalabs has approved a Rs 149 crore investment to develop a new Intermediate Block with a 405 KL capacity, targeting the CDMO segment. This capex represents approximately 7.5% of the company's net worth and is slated for completion within one year. Alongside this, the company reported robust Q1 FY27 standalone results, with revenue rising 42.4% YoY to Rs 534.6 crore and Net Profit increasing 49.3% YoY to Rs 71.3 crore. The board also approved the transition of Rashesh C. Gogri to Managing Director effective October 1, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has initiated a significant capacity expansion for its CDMO business and reported a sharp recovery in quarterly financial performance compared to the previous year.
ஏன் இது முக்கியம்The expansion into intermediates and CDMO services is a key part of the company's strategy to move up the value chain and reduce reliance on commoditized APIs, while the strong Q1 results indicate improved operational efficiency.
Proposed Capex: Rs 149 CroresCapacity Addition: 405 KLCapex vs Net Worth: ~7.5%Q1 Standalone Revenue Growth (YoY): 42.4%Q1 Standalone PAT Growth (YoY): 49.3%Completion Timeline: 1 ஆண்டு
📅 குறுகிய காலம்The stock is likely to react positively to the strong earnings growth and the clear roadmap for capacity expansion in high-margin segments.
📈 நீண்ட காலம்The 405 KL addition and the focus on CDMO services provide a structural growth lever for the next 2-3 years, potentially improving the company's return profile and market positioning.
⚠ அபாய எச்சரிக்கைகள்
Execution risk within the 1-year timeline
Increased debt levels as financing includes borrowings
👀 கவனிக்க வேண்டியவை
Monitor the execution of the 405 KL capacity addition over the next four quarters and observe if the strong Q1 margin performance is sustained amidst potential raw material price volatility.
₹149 Cr Capex for CDMO Expansion and Management Reshuffle at Aarti Pharmalabs
Aarti Pharmalabs reported a strong Q1 FY27 with standalone revenue of ₹534.59 cr, up 42.4% YoY from ₹375.31 cr. The board approved a fresh ₹149 cr investment to add 405 KL capacity for an Intermediate Block targeting CDMO customers, representing ~8.2% of TTM revenue. Leadership roles are shifting effective October 1, 2026, with Rashesh C. Gogri moving from Non-Executive to Managing Director. Standalone PAT for the quarter grew 49.3% YoY to ₹71.31 cr, reflecting improved operational performance.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has committed to a new capacity expansion for intermediates and reshuffled its top management roles while delivering strong double-digit earnings growth.
ஏன் இது முக்கியம்The ₹149 cr expansion specifically targets the high-margin CDMO segment, which is a key pillar for the company's long-term valuation re-rating beyond bulk drugs.
📅 குறுகிய காலம்The stock is likely to react positively to the 42% YoY revenue growth and the announcement of growth-oriented capex.
📈 நீண்ட காலம்The focus on CDMO capacity and the 1-year execution timeline for the new block suggests a clear path toward higher-margin revenue streams over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Execution risk for the 1-year capex timeline
Susceptibility to raw material price spikes affecting EBITDA margins
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the ₹149 cr intermediate block and the ramp-up of the Atali Greenfield site which is central to the company's CDMO growth strategy.
3,600 TPA Expansion: Aarti Pharmalabs Boosts Xanthine Capacity to 9,600 TPA at Tarapur
Aarti Pharmalabs has inaugurated a new 3,600 TPA manufacturing block for Xanthine derivatives at its Tarapur Unit 5 facility. This expansion increases the company's total capacity for these products to 9,600 TPA, representing a 60% increase from its previous base. The company now ranks among the top three global manufacturers of Xanthine derivatives, which are critical for the beverage and pharmaceutical industries. Trial production has commenced, with a full ramp-up expected over the next few quarters.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from the construction phase to the production phase for its Tarapur brownfield expansion, adding significant new capacity for its core Xanthine product line.
ஏன் இது முக்கியம்This expansion directly supports the company's goal of capturing a larger wallet share of the global beverage market and leverages its existing infrastructure to drive volume-led growth.
New Capacity Added: 3,600 TPATotal Post-Expansion Capacity: 9,600 TPACapacity Increase Percentage: 60%TTM வருவாய்: Rs 1,820 கோடிசந்தை மதிப்பு: Rs 6,238 கோடி
📅 குறுகிய காலம்The inauguration is a positive milestone that validates execution timelines; however, financial benefits will accrue gradually as production ramps up over the next 2-3 quarters.
📈 நீண்ட காலம்Strengthens the company's competitive position in the global nutraceutical and API supply chain, supporting its long-term growth target of 8-12%.
👀 கவனிக்க வேண்டியவை
Monitor the pace of capacity utilization ramp-up in the upcoming quarterly results and its impact on the current 21.2% operating margins. Watch for increased revenue contribution from the beverage segment as this facility reaches full scale.
Aarti Pharmalabs Q4 FY26: Revenue Up 9%, CDMO Segment Targets 40-50% Growth in FY27
Aarti Pharmalabs reported a 9% YoY revenue growth in Q4 FY26 to ₹580 crore, although full-year PAT declined to ₹176 crore, impacted by a ₹33 crore net foreign exchange loss. The CDMO segment remains a standout performer, growing 32% in FY26 and projected to grow 40-50% in FY27 as the Atali facility becomes fully operational. The company has maintained a strong growth guidance of 15-18% for both revenue and EBITDA over the next 3-4 years, supported by a ₹400 crore annual capex plan.
முக்கிய அம்சங்கள்
FY26 Revenue stood at ₹1,798 crore with EBITDA at ₹406 crore; Board declared a total dividend of ₹3.50 per share.CDMO segment reached record quarterly revenue of ₹155 crore with 54 active projects, including 35 in the commercial stage.Xanthine derivative capacity is expanding from 6,000 MTPA to 9,000 MTPA, with incremental production starting Q1 FY27.Atali Phase 1 (440 kL capacity) is expected to be completely operational by the end of Q1 FY27 after clearing customer audits.Company is investing in new R&D technologies including peptides and oligonucleotides for long-term future potential.
👀 கவனிக்க வேண்டியவை
Investors should focus on the execution of the CDMO segment's high-growth guidance and the successful ramp-up of the Atali facility to offset margin pressures in the API business. The stock remains a growth play with a clear 15-18% CAGR outlook, though short-term profitability has been impacted by forex and competitive headwinds.
Aarti Pharmalabs Q4 FY26: Revenue up 9.5% YoY to ₹580 Cr; CDMO Segment hits record high
Aarti Pharmalabs reported a 9.5% YoY increase in Q4 FY26 standalone revenue to ₹5,797 Mn, though EBITDA margins contracted to 23.1% from 31.2% in the previous year. The CDMO segment achieved its highest-ever quarterly revenue of ₹155 Cr, driven by large order deliveries. While annual PAT for FY26 declined by 31.5% to ₹1,762 Mn due to higher finance costs and forex impacts, the company is targeting a 15-18% CAGR over the next 3-4 years. Significant capacity expansions in Xanthine derivatives and the Atali greenfield project are expected to be fully operational by June 2026.
முக்கிய அம்சங்கள்
Q4 FY26 Standalone Revenue grew 9.5% YoY to ₹5,797 Mn, with CDMO revenue reaching a record ₹155 Cr.EBITDA margins for Q4 FY26 stood at 23.1%, down from 31.2% YoY, impacted by input costs and logistics.Xanthine capacity expansion to 9,000 MTPA and Atali Phase 1 (450 KL) to be fully operational by June 2026.FY26 Capex reached ~₹400 Cr, with a similar investment planned for FY27 including new R&D in TIDES.Management targets a 15-18% Revenue and EBITDA CAGR over the next 3-4 years.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin recovery as new capacities at Atali and Tarapur become operational in Q1 FY27. The strong growth in the high-margin CDMO segment is a positive long-term driver despite current bottom-line pressure.
Aarti Pharmalabs Limited has announced the completion of a US-FDA inspection at its Unit-IV facility in Tarapur, Maharashtra, on March 27, 2026. The inspection resulted in the issuance of a Form 483 with only one observation, which the company has characterized as procedural in nature. The company is committed to submitting corrective and preventive actions (CAPA) within the stipulated timeframe. This outcome is generally viewed as positive for a pharmaceutical company, as a single procedural observation suggests high compliance standards and minimal risk to existing operations.
முக்கிய அம்சங்கள்
US-FDA inspection at Unit-IV, Tarapur concluded on March 27, 2026Form 483 issued with only 01 (one) observationObservation is classified as procedural in nature rather than a data integrity or safety issueCompany to submit corrective and preventive actions (CAPA) within the required period
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory development as it indicates a low level of non-compliance. Monitor for the receipt of the Establishment Inspection Report (EIR) which will signify the formal closure of the inspection.
Aarti Pharmalabs Q3 FY26: Revenue at ₹425 Cr, PAT at ₹44 Cr; Declares ₹1.5 Interim Dividend
Aarti Pharmalabs reported a decline in Q3 FY26 revenue to ₹425 crores from ₹471 crores YoY, primarily due to pricing pressure in the API segment and operational delays at the new Atali plant. Profit After Tax (PAT) fell significantly to ₹44 crores compared to ₹74 crores in the same period last year. Management noted that ₹49 crores of revenue was deferred as goods in transit, which impacted the quarter's PBT by ₹19 crores. Consequently, the company has revised its FY26 outlook, expecting EBITDA to be largely in line with the previous year with only marginal growth.
முக்கிய அம்சங்கள்
Revenue decreased 9.8% YoY to ₹425 crores, while PAT dropped to ₹44 crores from ₹74 crores.Deferred revenue of ₹49 crores due to goods in transit impacted Q3 PBT by ₹19 crores, expected to be realized in Q4.CDMO segment remains a growth driver with 59 active projects, 40 of which are in the commercial stage.Atali plant Phase 1 (₹300 crore capitalized) faced stabilization hiccups, delaying some CDMO validation quantities to Q4.Board declared an interim dividend of ₹1.5 per share despite the earnings contraction.
👀 கவனிக்க வேண்டியவை
Investors should monitor the stabilization of the Atali plant and the ramp-up of Xanthine expansion in FY27, as FY26 growth is expected to be muted. The stock may face near-term pressure until API margins stabilize and new capacities begin contributing to the bottom line.
Aarti Pharmalabs Q3 Standalone PAT Falls 40% YoY to ₹43.8 Cr; EBITDA Margin Stable at 24.2%
Aarti Pharmalabs reported a 9.7% YoY decline in standalone revenue to ₹425.3 crore for Q3-FY26, while PAT dropped 40.4% YoY to ₹43.8 crore, impacted by higher depreciation and finance costs. Despite the YoY decline, the company showed a strong sequential recovery with EBITDA rising 39% QoQ and margins remaining resilient at 24.22%. The CDMO segment is a key growth driver with 30-40% growth projected for FY26, although ₹49 crore in revenue was deferred this quarter due to goods in transit. Major capacity expansions in Xanthine (to 9,000 MTPA) and the Atali greenfield site are nearing completion, positioning the company for future scale.
முக்கிய அம்சங்கள்
Standalone revenue for Q3-FY26 stood at ₹425.3 crore, down 9.7% YoY but up 1.9% QoQ.EBITDA margins remained stable at 24.22% vs 24.42% YoY, despite pricing pressures in the API segment.Xanthine capacity expansion from 5,000 MTPA to 9,000 MTPA is on track for completion by March 2026.CDMO segment currently has 59 active projects with 21 customers, expecting 30-40% revenue growth in FY26.Net Debt/Equity ratio remains low at 0.26x, supporting ongoing total capex plans of approximately ₹550 crore.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful ramp-up of the Atali greenfield site and the commissioning of the Xanthine expansion in Q4-FY26. While YoY earnings are soft, the sequential recovery and strong CDMO pipeline suggest long-term growth potential.
Aarti Pharmalabs Declares ₹1.5 Interim Dividend; Record Date Set for Feb 16, 2026
Aarti Pharmalabs Limited has announced an interim dividend of ₹1.5 per equity share for the financial year 2024-25, representing a 30% payout on the face value of ₹5. The decision was finalized during the Board of Directors meeting held on February 09, 2026. The company has designated February 16, 2026, as the record date to identify shareholders eligible for the payout. This move reflects the company's commitment to returning value to its shareholders through consistent payouts.
முக்கிய அம்சங்கள்
Interim dividend of ₹1.5 per equity share declared for FY 2024-25Dividend payout is 30% of the face value of ₹5 per shareRecord date for dividend eligibility is fixed as February 16, 2026Board meeting for the declaration took place on February 09, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend must ensure they hold the shares before the ex-dividend date, typically one working day prior to the February 16 record date. Long-term investors should view this as a positive sign of cash flow management.
Aarti Pharmalabs Q3 Net Profit at ₹47.96 Cr; Declares ₹1.50 Interim Dividend
Aarti Pharmalabs reported a consolidated net profit of ₹47.96 crore for the quarter ended December 31, 2025, a decline from ₹73.99 crore in the corresponding quarter of the previous year. Consolidated revenue from operations stood at ₹274.11 crore, which was impacted by ₹49.35 crore of revenue being deferred to Q4 due to goods being in transit. The company has declared an interim dividend of ₹1.50 per share (30% of face value). An exceptional item of ₹2.79 crore was recorded due to provisions for new labour codes.
முக்கிய அம்சங்கள்
Consolidated Net Profit for Q3 FY26 stood at ₹47.96 crore, down 35% YoY from ₹73.99 crore.Revenue from operations was ₹274.11 crore, with an additional ₹49.35 crore in-transit revenue deferred to Q4.Declared an interim dividend of ₹1.50 per equity share with a record date of February 16, 2026.Exceptional charge of ₹279.49 lakhs recognized for incremental provision under new labour codes.Consolidated EPS for the quarter fell to ₹5.29 from ₹8.16 in the year-ago period.
👀 கவனிக்க வேண்டியவை
Investors should monitor the Q4 results closely to see if the deferred revenue of ₹49.35 crore translates into a strong recovery in profitability. While the dividend provides some support, the year-on-year decline in earnings suggests a cautious approach until margins stabilize.
Aarti Pharmalabs Appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D
Aarti Pharmalabs has appointed Dr. Rakeshwar Bandichhor as Chief Scientific Officer for R&D and Senior Management Personnel, effective January 1, 2026. Dr. Bandichhor brings over 25 years of extensive experience in API-R&D and Process Chemistry to the company. He joins from Dr. Reddy's Laboratories and holds a Ph.D. with postdoctoral experience from prestigious institutions in Germany and the USA. This appointment is expected to strengthen the company's technical leadership and research capabilities in the pharmaceutical space.
முக்கிய அம்சங்கள்
Dr. Rakeshwar Bandichhor appointed as Chief Scientific Officer - R&D effective January 1, 2026Brings 25 years of rich experience in API-R&D and Process ChemistryPreviously associated with industry major Dr. Reddy's Laboratories in HyderabadHolds a Ph.D. and completed three postdoctoral trainings at universities in Germany and the USA
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards enhancing the company's R&D and API development capabilities. Monitor for future announcements regarding new product pipelines or process improvements under the new leadership.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
